Masterhead

Thank you for visiting brisbane.gate2bay.com. Fill in the form below:

Name/Corp.:

E-mail:

Subject:

Message:

Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

Published Aug 25 2014

Swiss pharmaceutical giant Roche remarked Sun it would buy Intermune of Brisbane, CA, for $8.3 billion. It’s by far the high water mark of a growing wave in recent years of deals for drugs to treat pulmonary fibrosis, a deadly scarring of the lungs that often has no known cause.

Intermune garnered such a high price because it has managed to bring a pulmonary fibrosis drug to market, the first drug maker to do so. Its pirfenidone, which treats the idiopathic version, is sold in Europe under the brand name Esbriet. It’s been approved in Canada, too, but the public health system won’t pay for it. America regulators should make the call on pirfenidone in late November.


Read more at
Xconomy

google-468x60a

Share This Post

DeliciousDiggGoogleStumbleuponRedditTechnoratiYahooBloggerMyspaceRSS

selfad-writeart-b